NANTONG, China, Dec. 12, 2025 /PRNewswire/ — Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated trial (IIT) of RAG-18 at Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences in Beijing. This milestone marks a transformative moment in the fight against Duchenne Muscular Dystrophy (DMD), positioning RAG-18 as a potential game-changer for the field. By utilizing a novel saRNA mechanism to upregulate UTRN expression, RAG-18 represents a revolutionary therapeutic approach that aims to overcome the limitations of current treatments and could provide a universal solution benefiting all patients affected by this devastating condition.

The IIT is led by Professor Dai Yi, a distinguished expert in neuromuscular disorders and the Deputy Director of the Neurology Department at PUMCH. The study aims to assess RAG-18’s safety and pharmacokinetic profile while exploring its potential to improve muscle function in DMD patients. Professor Dai stated, “We are excited to begin this clinical trial with RAG-18, a cutting-edge therapeutic approach for treating DMD. We anticipate positive clinical results that could open up new, innovative treatment options for patients and significantly improve their quality of life.”

Dr. Long-Cheng Li, the Founder and CEO of Ractigen Therapeutics, shared his enthusiasm about the trial, stating, “Starting this study is a crucial step forward for RAG-18, emphasizing its unique role in overcoming the challenges of DMD. This treatment has the potential to address all genetic mutations related to DMD, illustrating RNA activation (RNAa) technology as a revolutionary method in clinical practice and offering hope for previously untreatable conditions.”

About RAG-18
RAG-18 is a first of its kind saRNA candidate designed to specifically target and activate UTRN gene expression in muscle cells via RNAa mechanism. The utrophin protein encoded by the UTRN gene is structurally and functionally similar to dystrophin, and its upregulation could potentially serve as a functional replacement for the missing dystrophin in DMD muscle cells, providing treatment for all DMD patients regardless of the specific mutation location.

Preclinical data indicate that RAG-18, delivered utilizing Ractigen’s proprietary LiCO™ (lipid-conjugated oligonucleotide) technology, has effectively upregulated UTRN expression, mitigated muscle damage and improved muscle function, demonstrating significant potential in treating DMD patients. RAG-18 received Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the U.S. Food and Drug Administration (FDA) in 2024, underscoring its promise as a therapeutic option for patients with DMD.

About DMD
Duchenne Muscular Dystrophy (DMD) are severe genetic disorders caused by mutations in the dystrophin gene, leading to the absence or insufficiency of functional dystrophin protein. This protein is essential for muscle fiber stability. Without it, muscle cells are easily damaged and cannot repair themselves, resulting in progressive muscle weakness and degeneration. The dystrophin gene, the largest in the human body, contains 79 exons. Current disease-modifying therapeutic approaches for DMD include antisense oligonucleotides (ASO) mediated exon skipping, gene therapy, and gene editing, with exon skipping being the most common strategy. However, these treatments have significant limitations, highlighting the critical need for innovative therapies that target the root cause of DMD to provide more effective and long-lasting benefits for patients.

About RNAa
RNA activation is a clinically validated platform technology developed by Dr. Long-Cheng Li and his team. It utilizes saRNAs to target gene regulatory domains, activating gene expression and restoring therapeutic protein levels. This innovative technology holds vast potential for developing therapeutic drugs across various diseases, particularly where traditional methods fall short.

About Ractigen Therapeutics
Ractigen Therapeutics is a clinical-stage biopharmaceutical company innovating next-generation RNA therapeutics, with a primary focus on small activating RNAs (saRNAs) developed through its clinically validated RNA activation (RNAa) technology. Leveraging proprietary delivery platforms such as SCAD™, LiCO™, and GLORY™, Ractigen is advancing a robust pipeline addressing unmet medical needs in oncology, neurological diseases, and genetic disorders. Its versatile technologies also enable the rapid development of RNA-based solutions, including siRNAs, where applicable, to target life-threatening, fast-progressing conditions such as those in the CNS. Committed to scientific excellence and patient-centered innovation, Ractigen strives to transform healthcare through the power of RNA therapeutics. For more information, visit www.ractigen.com.

MONTEREY, Calif., Dec. 12, 2025 /PRNewswire/ — Retro Stage, the beloved vintage-inspired fashion brand, proudly unveils its 2025 Holiday Collection, “Vintage Christmas,” featuring vintage Christmas dresses and retro holiday outfits, now available for purchase. This year’s collection delves into the heart of mid-century festive style, reinterpreting iconic holiday elements through a lens of sophisticated elegance and modern wearability.

“The 2025 collection is a love letter to the most cherished symbols of a classic Christmas,” says the Retro Stage team. “We’ve deconstructed the festive palette and motifs—think rich velvet, iconic red-and-white, playful candy-cane stripes, and whimsical gingerbread accents—and reimagined them into timeless silhouettes that feel fresh yet forever.”

This year’s collection is artfully curated around three distinct but complementary festive narratives, reflecting the brand’s deep exploration of retro holiday fashion:

1. Luxe Velvet & Refined Romance

This theme centers on opulent velvet, highlighting the fabric’s inherent luster and graceful drape. Through classic tailoring and fluid lines, the collection presents velvet Christmas dresses and evening gowns that are perfect for formal dinners and gala events, where the garments catch and reflect festive lighting with captivating dimension.

2. Signature Festive Patterns & Playful Charm

Here, iconic holiday patterns are cleverly reinterpreted with a vintage touch. Signature plaids and stripes are rendered with attention to modern proportion and color balance, ensuring each piece retains joyful seasonal spirit while offering versatile styling potential for both special occasions and everyday wear.

3. Storytelling Details & Nostalgic Finishes

The collection incorporates thoughtful, narrative-driven details—from delicate vintage-inspired buttons to storytelling prints lining select pieces. These elements whisper of holiday traditions, adding unique personality and emotional warmth to each ensemble without overwhelming the overall design.

Every piece in the collection is meticulously crafted from premium materials, with a focus on construction quality and wearability. Retro Stage emphasizes versatile longevity, designing garments intended to become cherished staples in the wearer’s holiday wardrobe for years to come, aligning with a more mindful approach to festive fashion.

The Retro Stage 2025 Holiday “Vintage Christmas” Collection of vintage Christmas dresses, retro party outfits, and holiday accessories is now available exclusively at www.retro-stage.com.

About Retro Stage

Retro Stage is a popular vintage fashion brand featuring classic clothing and accessories inspired by 20th-century aesthetics. As a vintage style pioneer, Retro Stage is more than a brand; it’s a way of life, helping every customer explore the history of fashion through chic and glamorous retro style. “Beauty never fades,” said the Retro Stage team. “All we want to do is encourage women to build a better life for themselves and confidently embrace their natural allure.”

BEIJING, Dec. 12, 2025 /PRNewswire/ — ReTo Eco-Solutions, Inc. (Nasdaq: RETO) (“ReTo” or the “Company“) today announced that its wholly owned subsidiary, Beijing REIT Equipment Technology Co., Ltd. (“REIT Equipment“), is participating in Excon 2025, a major construction equipment exhibition in Bangalore, India. REIT Equipment is showcasing its advanced concrete equipment and intelligent solutions at the event.

Excon 2025, hosted in Bangalore’s tech and manufacturing hub, provides REIT Equipment with a key platform to engage with global industry professionals and potential buyers to address Indian market demands. Excon 2025’s focus, “Sustainable Development and Intelligent Construction,” aligns with REIT Equipment ‘s focus on green building materials equipment and intelligent solutions. During the event, REIT Equipment’s booth has generated interest from infrastructure developers, contractors, and government representatives nationwide.

Mr. Xinyang Li, Chief Executive Officer of ReTo, stated: “Upholding the philosophy of ‘growing with customers and communities,’ RETO reaffirms its commitment to the Indian market. It aims to continue embracing sustainable and intelligent construction trends, upgrading products and services to deliver a comprehensive value system supporting India’s infrastructure development.”

About ReTo Eco-Solutions, Inc.

Founded in 1999, ReTo Eco-Solutions, Inc., through its operating subsidiaries in China, is engaged in the research and development, manufacture and sales of ecological environment protection equipment and intelligent equipment. The Company provides consultation, design, implementation and installation of its equipment and related parts, as well as engineering support and technical advice and services. For more information, please visit: http://en.retoeco.com.  

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. The Company’s actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the Company’s globalization strategy, future collaborations, technological developments, production capabilities, operational efficiencies, anticipated benefits to clients, and the potential impact on the Indian market. The reports filed by the Company with the Securities and Exchange Commission discuss these and other important factors and risks that may affect the Company’s business, results of operations and financial conditions. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

ReTo Eco-Solutions, Inc.
Tel: +86-10-64827328
Email: ir@retoeco.com or 310@reit.cc

BEIJING, Dec. 12, 2025 /PRNewswire/ — Youlife Group Inc. (“Youlife” or the “Company”) (NASDAQ: YOUL), a leading blue-collar lifetime service provider in China, today announced that it has entered into a non-binding letter of intent (the “LOI”), expressing its intention to acquire four regional human resources service companies (the “Target Companies”) through a proposed pure-equity transaction. The LOI represents a major step in the Youlife’s evolution from pure organic growth to a dual-engine strategy combining organic expansion and strategic M&A.

Under the non-binding LOI, Youlife and the sellers intend to undertake an internal restructuring to consolidate the Target Companies under an offshore holding structure. Upon completion of this restructuring, Youlife may consider acquiring the holding entity through an equity-based transaction involving newly issued shares of Youlife, subject to further evaluation, due diligence, valuation, and negotiation and execution of definitive agreements.

The contemplated structure is designed to preserve cash resources while aligning long-term interests between both parties. Any potential share consideration is expected to include performance-based mechanisms that would help safeguard shareholder value and ensure ongoing alignment. All terms remain under discussion, and the LOI does not obligate either party to proceed unless and until definitive agreements are executed.

The Target Companies have long-standing operations in job placement, flexible staffing, and regional workforce management across multiple provinces in China. They have strong presence in labor-intensive verticals such as logistics and livestock farming, serving key clients include market-leading enterprises. The intended acquisition will reinforce Youlife’s full-cycle blue-collar service ecosystem, which spans vocational education, recruitment, and employee management. If completed, the acquisition is expected to broaden Youlife’s geographic reach, enhance network density, and create opportunities for future operational synergies.

Mr. Yunlei Wang, Chief Executive Officer and Chairman of the Board of Youlife, emphasized, “This LOI represents a meaningful step in our commitment to integrating regional strengths into a unified, high-quality, nationwide blue-collar service platform. China’s blue-collar human resources sector is undergoing significant transformation, driven by industrial upgrading, rising compliance requirements, and the rapid adoption of digital and AI-enabled workforce solutions. These trends are creating new opportunities for consolidation and platform-driven models.

Upon completion, we believe the Target Companies’ regional expertise, combined with Youlife’s nationwide ecosystem and our AI-powered ‘DeepBlue Brain’ matching engine, could enhance our ability to deliver standardized, efficient, and technology-driven workforce solutions across the country. This is a meaningful step forward in strengthening Youlife’s long-term development path and leadership position in China’s blue-collar service market.”

Ms. Liqun Yao, acting Chief Financial Officer of Youlife, added, “The non-binding LOI reflects our disciplined approach to evaluating strategic opportunities. By using an equity-based structure tied to the future performance of the acquired businesses, we would be able to preserve cash, maintain financial flexibility, and align incentives with long-term shareholder value.”

The Company has not entered into definitive transaction agreements with the sellers, and the execution of any definitive agreements is contingent upon the commercial negotiations with the sellers and the completion of the relevant legal and financial due diligence. There is no guarantee that the contemplated transactions will take place under the current terms or timeline, or at all. Shareholders are cautioned not to place undue reliance on this preliminary announcement.

About Youlife Group Inc.

Youlife is a leading blue-collar lifetime service provider with a nationwide network of 25 vocational schools under school management model and 25 curriculum development projects, covering a total of 37 cities or counties under 16 provinces of China. Learn more at https://ir.youlife.cn/.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements also include, but are not limited to, statements regarding future events and the future results of Youlife current expectations, estimates, forecasts, and projections about the industry in which Youlife operates, as well as the beliefs and assumptions of Youlife’s management. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Youlife’s management and are not predictions of actual performance. These statements involve risks, uncertainties and other factors that may cause Youlife’s actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by these forward-looking statements.

Contact 
Sufang Fu
youlife.ir@youlanw.com
(86) 18280935910